Chang Hung Kiang

ORCID: 0000-0002-6274-4510 · 2 papers in corpus · active 2023-2025

Study types

  • article 2
article 2025
Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia
·doi:10.1007/s12185-025-04037-6

INTRODUCTION: This post hoc analysis investigated the efficacy and safety of momelotinib in the Asian subpopulation of MOMENTUM (NCT04173494). METHODS: Patients were randomized 2:1 to momelotinib 200 mg once daily (QD) plus danazol placebo …

article 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
·doi:10.1016/s0140-6736(22)02036-0